Market Intel

10 articles this week

TCGX (TCGX) to Combine with TriGemX Bio in $403M Deal

TCGX I (NASDAQ:TCGX) has signed a definitive agreement to combine with drug developer TriGemX Bio at a pro forma enterprise value of $402.8 million. New York-based TriGemX Bio is developing a drug candidate for the treatment of acute migraines that is currently in Phase III trials. More

Nicholas Alan Clayton·Oct 19

Morning SPAC News Roundup: October 19, 2026

The third week of October is set to host three SPAC shareholder votes and could include as many or more IPOs with AEI CapForce II (NASDAQ:AEIBU), SPACCircle (NASDAQ:SCQCU), Allarity (NASDAQ:ALLNU), and Harbour Island I (NASDAQ:HRIAU) all lined up to attempt to price their offerings this week. More

Nicholas Alan Clayton·Oct 19

SPAC IPO Terms Tracker: October 16, 2026

Terms Tracker for the Week Ending October 16, 2026 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week's pricings. Two more IPOs priced this week, bringing the October count to four and the 2026 year-to-date count to 156. More

Kristi Marvin·Oct 17

New SPAC: EuroSPAC Acquisition Corp. Files for $125M IPO

EuroSPAC Acquisition Corp. has filed for a $125 million SPAC with a team made up of executives from the shipping industry. The new SPAC is offering investors 1/2 warrants in its units with no overfunding of its trust and a 24-month transaction deadline. More

Nicholas Alan Clayton·Oct 16

TCGX Acquisition Corp. II (TCXB) Prices $100M IPO

TCGX Acquisition Corp. II (NASDAQ:TCXB) announced the pricing of its $100 million IPO and its shares are expected to begin trading on the Nasdaq under the symbol "TCXB" on Friday, October 16, 2026. More

Nicholas Alan Clayton·Oct 15

Top 3 SPAC Targets – Insurance

In the last iteration of this column, SPACInsider took a look at some industries and targets that should be high on a SPAC team’s list, especially should inflation and interest rate pressures force a renewed focus on cash-generating targets. More

Nicholas Alan Clayton·Oct 15

Pyrophyte II (PAII) to Combine with Sakuu Corporation in $682M Deal

Pyrophyte II (NYSE:PAII) has entered into a definitive agreement to combine with manufacturing firm Sakuu at a pro forma enterprise value of $682.3 million. San Jose, California-based Sakuu is developing manufacturing lines for more efficiently producing battery materials for a number of industries. More

Nicholas Alan Clayton·Oct 15

Frazier Life Sciences Acquisition Corp. II (FLSC) Prices $75M IPO

Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) announced the pricing of its $75 million IPO and its shares are expected to begin trading on the Nasdaq under the symbol "FLSC" on Wednesday, October 14, 2026. More

Nicholas Alan Clayton·Oct 13

New SPAC: Apex Treasury Corp II (APTTU) Files for $250M IPO

Apex Treasury Corp II (NASDAQ:APTTU) has filed for a $250 million SPAC to look at AI targets as well as a number of other hot sectors. The new SPAC is offering investors a 1/3 warrant in each unit, but it will not be overfunding its trust or shortening its transaction deadline from 24 months. More

Nicholas Alan Clayton·Oct 13

Horizon Space I (HSPOF) to Combine with ArcheNova Biotech in $2Bn Deal

Horizon Space I (OTC:HSPOF) has entered into a definitive agreement to combine with ArcheNova Biotech at a $2 billion valuation. ArcheNova is developing a series of drug candidates and offering its own discovery platform to other firms in the biotech space. More

Nicholas Alan Clayton·Oct 13